EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Real World Effectiveness of Durvalumab in Stage III Unresectable Non-small Cell Lung Cancer: What is the Role of PD-L1 Expression?

Hanieh Abedian Kalkhoran, Marjon V Verschueren, Bas J M Peters, Ewoudt M W van de Garde, Egbert F Smit, Stefan Bohringer, Danielle Cohen, Judith L Gulikers, Henk Codrington, Henk-Jan Guchelaar, Loes E Visser, Juliëtte Zwaveling

Clinical Lung Cancer · 2025

DOI: 10.1016/j.cllc.2025.07.009 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Clinical Lung Cancer, 2025. Verfasst von Hanieh Abedian Kalkhoran und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, the Netherlands; Department of Pharmacy, Haga Teaching Hosp…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, B7-H1 Antigen, Antibodies, Monoclonal. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: Although the European Medicines Agency approved durvalumab post-chemoradiation (CRT) only for stage III unresectable non-small cell lung cancer (UR-NSCLC) patients with PD-L1 tumor proportion scores (TPS) ≥ 1%, the Netherlands offers reimbursement irrespective of PD-L1 status. This real-world study compares survival between durvalumab-treated patients with PD-L1 TPS < 1% vs. ≥ 1%, and also evaluates its effectiveness against a historic-cohort. PATIENTS AND METHODS: This multicenter retrospective study included 2 patient cohorts with stage III UR-NSCLC: a durvalumab cohort and a historic CRT-only cohort. The durvalumab cohort was divided into PD-L1 TPS subgroups: < 1%, ≥ 1%, and unknown. Overall survival (OS) and progression-free survival (PFS) were compared between (1) durvalumab-treated patients with PD-L1 TPS < 1% vs. ≥ 1%, and (2) durvalumab cohort (including PD-L1 subgroups) vs. historic-cohort. RESULTS: 229 and 339 patients were included in the durvalumab- and historic-cohorts, respectively. Although not statistically significant, durvalumab-treated patients with PD-L1 TPS ≥ 1% experienced a modestly greater benefit in OS (2-year OS 74.3% vs. 66.5%) and PFS (2-year PFS 55.5% vs. 36.2%) compared to those with PD-L1 TPS < 1%. Survival outcomes favored durvalumab over the historic cohort across PD-L1 subgroups, though PFS improvement was not statistically significant for PD-L1 TPS < 1%. CONCLUSIONS: Given these findings, patients with PD-L1 TPS < 1% may also benefit from durvalumab treatment in stage III UR-NSCLC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsB7-H1 AntigenAntibodies, MonoclonalAntineoplastic Agents, ImmunologicalHumansMaleRetrospective StudiesFemaleMiddle AgedAgedNeoplasm StagingSurvival RateAged, 80 and overFollow-Up StudiesAdultPrognosis

Stichwörter der Autor:innen

Immune Checkpoint InhibitorImmunotherapyNegative PD-L1PD-L1 TPS

Substanzen

durvalumabB7-H1 AntigenAntibodies, MonoclonalCD274 protein, humanAntineoplastic Agents, Immunological

Autor:innen und Institutionen

  • Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, the Netherlands; Department of Pharmacy, Haga Teaching Hospital, The Hague, the Netherlands. Electronic address: h.abedian_kalhor…
  • Department of Clinical Pharmacy, St. Antonius Hospital, Utrecht, the Netherlands; Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, t…
  • Department of Clinical Pharmacy, St. Antonius Hospital, Utrecht, the Netherlands.
  • Department of Thoracic Oncology, Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands; Department of Pulmonary Diseases, Leiden University Medical Centre, Leiden, the Netherlands.
  • Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, the Netherlands; Department of Biomedical Data Sciences, Leiden University Medical Center, Leiden, The Netherlands.
  • Department of Pathology, Leiden University Medical Centre, Leiden, the Netherlands.

Zitieren

APA

Kalkhoran, H. A., Verschueren, M. V., Peters, B. J. M., van de Garde, E. M. W., Smit, E. F., Bohringer, S., Cohen, D., Gulikers, J. L., Codrington, H., Guchelaar, H. J., Visser, L. E., & Zwaveling, J. (2025). Real World Effectiveness of Durvalumab in Stage III Unresectable Non-small Cell Lung Cancer: What is the Role of PD-L1 Expression?. Clinical Lung Cancer. https://doi.org/10.1016/j.cllc.2025.07.009

Vancouver

Kalkhoran HA, Verschueren MV, Peters BJM, van de Garde EMW, Smit EF, Bohringer S, et al. Real World Effectiveness of Durvalumab in Stage III Unresectable Non-small Cell Lung Cancer: What is the Role of PD-L1 Expression?. Clinical Lung Cancer. 2025. doi:10.1016/j.cllc.2025.07.009

BibTeX
@article{Kalkhoran2025,
  author = {Kalkhoran, Hanieh Abedian and Verschueren, Marjon V and Peters, Bas J M and van de Garde, Ewoudt M W and Smit, Egbert F and Bohringer, Stefan and Cohen, Danielle and Gulikers, Judith L and Codrington, Henk and Guchelaar, Henk-Jan and Visser, Loes E and Zwaveling, Juliëtte},
  title = {Real World Effectiveness of Durvalumab in Stage III Unresectable Non-small Cell Lung Cancer: What is the Role of PD-L1 Expression?},
  journal = {Clinical Lung Cancer},
  year = {2025},
  doi = {10.1016/j.cllc.2025.07.009}
}
Kostenlos starten →